Pettingale K W
Clin Radiol. 1981 Sep;32(5):553-6. doi: 10.1016/s0009-9260(81)80186-9.
This report describes a comparison of combination chemotherapy (CHOP) with total body irradiation (TBI) in the management of Stages III and IV Grade 2 non-Hodgkin's lymphoma. This prospective randomised study was carried out by the BNLI between 1974 and 1978. One hundred and fourteen previously untreated patients were accepted: 66 received CHOP and 48 TBI. Complete remission was obtained in 39% of patients treated with CHOP and 23% with TBI. This difference is not significant. However, when comparison is stratified for Stage III disease the survival of the CHOP-treated group is statistically significant (chi(2) = 4.125: 0.05 greater than P greater than 0.025). This difference in favour of CHOP is most marked in patients with poorly differentiated histology. Only 46% of patients receiving CHOP remain alive at the time of this report. There is urgent need for more effective treatment in the management of this type of lymphoma.
本报告描述了在Ⅲ期和Ⅳ期2级非霍奇金淋巴瘤的治疗中，联合化疗（CHOP方案）与全身照射（TBI）的比较。这项前瞻性随机研究由英国国家淋巴瘤研究组（BNLI）于1974年至1978年进行。114例未经治疗的患者入组：66例接受CHOP方案治疗，48例接受TBI治疗。接受CHOP方案治疗的患者中39%获得完全缓解，接受TBI治疗的患者中这一比例为23%。这一差异无统计学意义。然而，当按Ⅲ期疾病进行分层比较时，CHOP治疗组的生存率具有统计学意义（χ² = 4.125，0.05＞P＞0.025）。这种有利于CHOP方案的差异在组织学分化差的患者中最为明显。在撰写本报告时，接受CHOP方案治疗的患者中仅有46%存活。对于这类淋巴瘤的治疗，迫切需要更有效的治疗方法。
